Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. Methods: Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26. Results: At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients. Conclusions: Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624.

Eculizumab improves fatigue in refractory generalized myasthenia gravis / Andersen H.; Mantegazza R.; Wang J.J.; O'Brien F.; Patra K.; Howard J.F.; Mazia C.G.; Wilken M.; Barroso F.; Saba J.; Rugiero M.; Bettini M.; Chaves M.; Vidal G.; Garcia A.D.; DeBleecker J.; Van denAbeele G.; deKoning K.; DeMey K.; Mercelis R.; Mahieu D.; Wagemaekers L.; VanDamme P.; Depreitere A.; Schotte C.; Smetcoren C.; Stevens O.; VanDaele S.; Vandenbussche N.; Vanhee A.; Verjans S.; Vynckier J.; D'Hondt A.; Tilkin P.; AlvesdeSiqueira Carvalho A.; DiasBrockhausen I.; Feder D.; Ambrosio D.; Cesar P.; Melo A.P.; MartinsRibeiro R.; Rocha R.; BezerraRosa B.; Veiga T.; daSilva L.A.; SantosEngel M.; GoncalvesGeraldo J.; daPenha AnaniasMorita M.; NogueiraCoelho E.; Paiva G.; Pozo M.; Prando N.; MartineliTorres D.D.; Butinhao C.F.; Duran G.; Gomes daSilva T.C.; Otavio MaiaGoncalves L.; Pazetto L.E.; Fialho T.A.S.; Renata CubasVolpe L.; SouzaDuca L.; GhellerFriedrich M.A.; Guerreiro A.; Mohr H.; PereiraMartins M.; daCruz Pacheco D.; Ferreira L.; Macagnan A.P.; Pinto G.; deCassia Santos A.; Souza BulleOliveira A.; AmaralAndrade A.C.; Annes M.; Duarte Silva L.; CavalcanteLino V.; Pinto W.; Assis N.; Carrara F.; Miranda C.; Souza I.; Fernandes P.; Siddiqi Z.; Phan C.; Narayan J.; Blackmore D.; Mallon A.; Roderus R.; Watt E.; Vohanka S.; Bednarik J.; Chmelikova M.; Cierny M.; Toncrova S.; Junkerova J.; Kurkova B.; Reguliova K.; Zapletalova O.; Pitha J.; Novakova I.; Tyblova M.; Jurajdova I.; Wolfova M.; Harbo T.; Vinge L.; Krogh S.; Mogensen A.; Vissing J.; Hojgaard J.; Witting N.; OstergaardAutzen A.; Pedersen J.; Eralinna J.-P.; Laaksonen M.; Oksaranta O.; Harrison T.; Eriksson J.; Rozsa C.; Horvath M.; Lovas G.; Matolcsi J.; Szabo G.; Jakab G.; Szabadosne B.; Vecsei L.; Dezsi L.; Varga E.; Konyane M.; Antonini G.; DiPasquale A.; Garibaldi M.; Morino S.; Troili F.; Fionda L.; Filla A.; Costabile T.; Marano E.; Sacca F.; Fasanaro A.; Marsili A.; Puorro G.; Antozzi C.; Bonanno S.; Camera G.; Locatelli A.; Maggi L.; Pasanisi M.; Campanella A.; Evoli A.; Alboini P.E.; D'Amato V.; Iorio R.; Inghilleri M.; Fionda L.; Frasca V.; Giacomelli E.; Gori M.; Lopergolo D.; Onesti E.; Frasca V.; Gabriele M.; Uzawa A.; Kanai T.; Kawaguchi N.; Mori M.; Kaneko Y.; Kanzaki A.; Kobayashi E.; Murai H.; Masaki K.; Matsuse D.; Matsushita T.; Uehara T.; Shimpo M.; Jingu M.; Kikutake K.; Nakamura Y.; Sano Y.; Utsugisawa K.; Nagane Y.; Kamegamori I.; Tsuda T.; Fujii Y.; Futono K.; Ozawa Y.; Mizugami A.; Saito Y.; Suzuki H.; Morikawa M.; Samukawa M.; Kamakura S.; Miyawaki E.; Shiraishi H.; Mitazaki T.; Motomura M.; Mukaino A.; Yoshimura S.; Asada S.; Yoshida S.; Amamoto S.; Kobashikawa T.; Koga M.; Maeda Y.; Takada K.; Takada M.; Tsurumaru M.; Yamashita Y.; Suzuki Y.; Akiyama T.; Narikawa K.; Tano O.; Tsukita K.; Kurihara R.; Meguro F.; Fukuda Y.; Sato M.; Okumura M.; Funaka S.; Kawamura T.; Makamori M.; Takahashi M.; Taichi N.; Hasuike T.; Higuchi E.; Kobayashi H.; Osakada K.; Imai T.; Tsuda E.; Shimohama S.; Hayashi T.; Hisahara S.; Kawamata J.; Murahara T.; Saitoh M.; Suzuki S.; Yamamoto D.; Ishiyama Y.; Ishiyama N.; Noshiro M.; Takeyama R.; Uwasa K.; Yasuda I.; van derKooi A.; deVisser M.; Gibson T.; Kim B.-J.; Lee C.N.; Koo Y.S.; Seok H.Y.; Kang H.N.; Ra H.J.; Kim B.J.; Cho E.B.; Choi M.S.; Lee H.L.; Min J.-H.; Seok J.; Lee J.E.; Koh D.Y.; Kwon J.Y.; Park S.A.; Choi E.H.; Hong Y.-H.; Ahn S.-H.; Koo D.L.; Lim J.-S.; Shin C.W.; Hwang J.Y.; Kim M.; Kim S.M.; Jeong H.-N.; Jung J.W.; Kim Y.-H.; Lee H.S.; Shin H.Y.; Hwang E.B.; Shin M.; Casasnovas C.; AlbertiAguilo M.A.; Homedes-Pedret C.; JuliaPalacios N.; DiezPorras L.; VelezSantamaria V.; Lazaro A.; DiezTejedor E.; Gomez Salcedo P.; Fernandez-Fournier M.; LopezRuiz P.; Rodriguez deRivera F.J.; Sastre M.; Gamez J.; Sune P.; Salvado M.; Gili G.; Mazuela G.; Illa I.; CortesVicente E.; Diaz-Manera J.; QuerolGutierrez L.A.; RojasGarcia R.; Vidal N.; Arribas-Ibar E.; Piehl F.; Hietala A.; Bjarbo L.; Sengun I.; Meherremova A.; Ozcelik P.; Balkan B.; Tuga C.; Ugur M.; Erdem-Ozdamar S.; Bekircan-Kurt C.E.; Acar N.P.; Yilmaz E.; Caliskan Y.; Orsel G.; Efendi H.; Aydinlik S.; Cavus H.; Kutlu A.; Becerikli G.; Semiz C.; Tun O.; Terzi M.; Dogan B.; Onar M.K.; Sen S.; KirbasCavdar T.; Veske A.; Norwood F.; Dimitriou A.; Gollogly J.; Mahdi-Rogers M.; Seddigh A.; Sokratous G.; Maier G.; Sohail F.; Jacob S.; Sadalage G.; Torane P.; Brown C.; Shah A.; Sathasivam S.; Arndt H.; Davies D.; Watling D.; Amato A.; Cochrane T.; Salajegheh M.; Roe K.; Amato K.; Toska S.; Wolfe G.; Silvestri N.; Patrick K.; Zakalik K.; Katz J.; Miller R.; Engel M.; Forshew D.; Bravver E.; Brooks B.; Plevka S.; Burdette M.; Cunningham S.; Sanjak M.; Kramer M.; Nemeth J.; Schommer C.; Tierney S.; Juel V.; Guptill J.; Hobson-Webb L.; Massey J.; Beck K.; Carnes D.; Loor J.; Anderson A.; Pascuzzi R.; Bodkin C.; Kincaid J.; Snook R.; Guingrich S.; Micheels A.; Chaudhry V.; Corse A.; Mosmiller B.; Kelley A.; Ho D.; Srinivasan J.; Vytopil M.; Jara J.; Ventura N.; Scala S.; Carter C.; Donahue C.; Herbert C.; Weiner E.; Alam S.; McKinnon J.; Haar L.; McKinnon N.; Alcon K.; McKenna K.; Sattar N.; Daniels K.; Jeffery D.; Kissel J.; Freimer M.; Hoyle J.C.; Agriesti J.; Chelnick S.; Mezache L.; Pineda C.; Muharrem F.; Karam C.; Khoury J.; Marburger T.; Kaur H.; Dimitrova D.; Gilchrist J.; Agrawal B.; Elsayed M.; Kohlrus S.; Andoin A.; Darnell T.; Golden L.; Lokaitis B.; Seelback J.; Muppidi S.; Goyal N.; Sakamuri S.; So Y.T.; Paulose S.; Pol S.; Welsh L.; Bhavaraju-Sanka R.; TobonGonzales A.; Dishman L.; Jones F.; Gonzalez A.; Padilla P.; Saklad A.; Silva M.; Nations S.; Trivedi J.; Hopkins S.; Kazamel M.; Alsharabati M.; Lu L.; Nozaki K.; Mumfrey-Thomas S.; Woodall A.; Mozaffar T.; Cash T.; Goyal N.; Roy G.; Mathew V.; Maqsood F.; Minton B.; Jones H.J.; Rosenfeld J.; Garcia R.; Echevarria L.; Garcia S.; Pulley M.; Aranke S.; Berger A.R.; Shah J.; Shabbir Y.; Smith L.; Varghese M.; Gutmann L.; Gutmann L.; Jerath N.; Nance C.; Swenson A.; Olalde H.; Kressin N.; Sieren J.; Barohn R.; Dimachkie M.; Glenn M.; McVey A.; Pasnoor M.; Statland J.; Wang J.; Liu T.; Emmons K.; Jenci N.; Locheke J.; Fondaw A.; Johns K.; Rico G.; Walsh M.; Herbelin L.; Hafer-Macko C.; Kwan J.; Zilliox L.; Callison K.; Young V.; DiSanzo B.; Naunton K.; Benatar M.; Bilsker M.; Sharma K.; Cooley A.; Reyes E.; Michon S.-C.; Sheldon D.; Steele J.; Karam C.; Chopra M.; Traub R.; Vu T.; Katzin L.; McClain T.; Harvey B.; Hart A.; Huynh K.; Beydoun S.; Chilingaryan A.; Doan V.; Droker B.; Gong H.; Karimi S.; Lin F.; McClain T.; Pokala K.; Shah A.; Tran A.; Akhter S.; Malekniazi A.; Tandan R.; Hehir M.; Waheed W.; Lucy S.; Weiss M.; Distad J.; Strom S.; Downing S.; Kim B.; Bertorini T.; Arnold T.; Hendersen K.; Pillai R.; Liu Y.; Wheeler L.; Hewlett J.; Vanderhook M.; Nowak R.; Dicapua D.; Keung B.; Kumar A.; Patwa H.; Robeson K.; Yang I.; Nye J.; Vu H.. - In: QUALITY OF LIFE RESEARCH. - ISSN 0962-9343. - ELETTRONICO. - 28:(2019), pp. 2247-2254. [10.1007/s11136-019-02148-2]

Eculizumab improves fatigue in refractory generalized myasthenia gravis

D'Amato V.
Membro del Collaboration Group
;
2019

Abstract

Purpose: To evaluate the effect of eculizumab on perceived fatigue in patients with anti-acetylcholine receptor antibody-positive, refractory, generalized myasthenia gravis (MG) using the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue subscale, and to evaluate correlations between improvements in Neuro-QOL Fatigue and other clinical endpoints. Methods: Neuro-QOL Fatigue, MG Activities of Daily Living (MG-ADL), Quantitative MG (QMG), and the 15-item MG Quality of Life (MG-QOL15) scales were administered during the phase 3, randomized, placebo-controlled REGAIN study (eculizumab, n = 62; placebo, n = 63) and subsequent open-label extension (OLE). Data were analyzed using repeated-measures models. Correlations between changes in Neuro-QOL Fatigue and in MG-ADL, QMG, and MG-QOL15 scores were determined at REGAIN week 26. Results: At REGAIN week 26, eculizumab-treated patients showed significantly greater improvements in Neuro-QOL Fatigue scores than placebo-treated patients (consistent with improvements in MG-ADL, QMG, and MG-QOL15 scores previously reported in REGAIN). Improvements with eculizumab were sustained through OLE week 52. Correlations between Neuro-QOL Fatigue and MG-QOL15, MG-ADL, and QMG scores were strong for eculizumab-treated patients at REGAIN week 26, and strong, moderate, and weak, respectively, for placebo-treated patients. Conclusions: Compared with placebo, eculizumab was associated with improvements in perceived fatigue that strongly correlated with improvements in MG-specific outcome measures. Trial ID Registration: NCT01997229, NCT02301624.
2019
28
2247
2254
Andersen H.; Mantegazza R.; Wang J.J.; O'Brien F.; Patra K.; Howard J.F.; Mazia C.G.; Wilken M.; Barroso F.; Saba J.; Rugiero M.; Bettini M.; Chaves M...espandi
File in questo prodotto:
File Dimensione Formato  
Eculizumab improves fatigue in refractory generalized myasthenia gravis.pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 764.69 kB
Formato Adobe PDF
764.69 kB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1258326
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 31
social impact